IRVINE, Calif., May 10, 2012 /PRNewswire/ -- Aviir Diagnostic Laboratory has entered into a contractual agreement for ancillary diagnostic laboratory testing as a participating provider with Stratose Network and their 8.6 million lives network.
A true pioneer of claims optimization, Stratose (formerly operating as Coalition America, NPPN, OPPN, PlanCare America, 4MOST Health, Qualident and KeyClaims) works to reduce the cost and ensure the best financial results on every medical, dental and workers' compensation claim for insurance carriers, TPAs, HMOs, stop-loss carriers and Labor/Taft- Hartley funds. Through our powerful combination of personal relationships, proprietary data and hands-on claims review, we have delivered a history of savings for our clients—over $10 billion since 1995.
Coalition America, a leader in healthcare cost containment services for medical, dental and workers' compensation claims, is pleased to announce the company and its affiliate brands have been consolidated and rebranded as Stratose. The new brand, including name, logo and web presence, better reflects the company's key market position. The company is able to apply network relationships and proprietary technology to deliver optimal savings on healthcare claims for payors.
The company's new name and brand are founded on a stratified view of claims cost management. Instead of the traditional in- or out-of-network categories, Stratose evaluates all claim types to identify opportunities for savings. "By drilling deeper into these categories, we can better leverage network relationships, creative service solutions and data analytics to deliver the best financial results for everyone involved," Stratose President Tina Ellex says.
"Since 1995, we have ensured the best savings results for payor customers," says Ellex. "We are continuing to drive greater value for our customers as Stratose. We positively impact the industry in terms of job growth, lower healthcare costs and access to quality care."
Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests that will assist in identifying patients that are truly at high risk for the development of a cardiac event. Aviir's proprietary MiRisk™ and TruRisk™ assessments objectively identify, by a simple blood draw, individuals who are at a high risk of a cardiac event over the next five years. Aviir's CLIA laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders – including pharmacogenomics and genetic tests. www.aviir.com
"There is currently a significant yet unmet clinical need in the medical community for more effective ways to identify individuals at high risk of a heart attack who are missed by current evaluation methods. Providing an accurate assessment of the patient's overall heart health is the first step in prevention of cardiovascular disease," stated Douglas Harrington, M.D., Chief Executive Officer of Aviir.
"At Aviir, our ultimate goal is to help physicians identify those patients who are at serious risk of experiencing a heart attack but are completely unaware of their precarious condition. Armed with better information, physicians will be able to customize individualized treatment plans with the goal of improving patient therapeutic compliance, reduce their risk of heart attacks, and decrease the overall cost of care," Dr. Harrington added.
|SOURCE Aviir Diagnostic Laboratory|
Copyright©2010 PR Newswire.
All rights reserved